News & Updates
Filter by Specialty:
Ketogenic trials with Parkinson’s disease-specific outcomes lacking
The ketogenic diet, as well as ketogenic agents, has been shown to be a promising therapeutic regimen for Parkinson’s disease (PD) in animals, but research on humans is highly heterogenous and lacking PD-specific outcomes, according to a study.
Ketogenic trials with Parkinson’s disease-specific outcomes lacking
19 Jun 2022
Dulaglutide: A new horizon for T2D treatment in kids
A once-weekly subcutaneous dose of the GLP-1* receptor agonist dulaglutide successfully controlled glycaemic levels in youths with type 2 diabetes (T2D) being treated with lifestyle modification with or without metformin or insulin, results of the multinational, phase III AWARD-PEDS** study showed.
Dulaglutide: A new horizon for T2D treatment in kids
18 Jun 2022
Bimekizumab shows promise across the spectrum of axial spondyloarthritis
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
Bimekizumab shows promise across the spectrum of axial spondyloarthritis
18 Jun 2022
RELIEVE-AD: Atopic dermatitis patients see rapid, sustained improvements with dupilumab
The biologic dupilumab appears to be a hit with atopic dermatitis (AD) patients treated in the real-world setting, with patients experiencing prompt improvements in multiple aspects of disease control that persisted through 1 year, as shown in the results of the RELIEVE-AD* study.
